EHC Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.54B

+9.65%

1.302

+11.28%

1.58B

+8.85%

1.497

+9.23%

1.58B

+8.66%

1.473

+5.22%

Estimates Revision

The market is revising Downward the revenue expectations for Encompass Health Corporation (EHC) for FY2025, with the revenue forecasts being adjusted by -0.05% over the past three months. During the same period, the stock price has changed by -16.43%.

Revenue Estimates for FY2025

Revise Downward

-0.05%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-16.43%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast EHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EHC is 142.80 USD with a low forecast of 134.00 USD and a high forecast of 150.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

134.00

Averages

142.80

High

150.00

Current: 0.000

Low

134.00

Averages

142.80

High

150.00

Barclays

Andrew Mok

Overweight

maintain

$141 -> $150

2025-10-30

Reason

Barclays

Andrew Mok

Price Target

$141 -> $150

2025-10-30

maintain

Overweight

Reason

Barclays analyst Andrew Mok raised the firm's price target on Encompass Health to $150 from $141 and keeps an Overweight rating on the shares. The company reported a modest Q4 beat, the analyst tells investors in a research note.

KeyBanc

Overweight

maintain

$135 -> $140

2025-09-16

Reason

KeyBanc

Price Target

$135 -> $140

2025-09-16

maintain

Overweight

Reason

KeyBanc raised the firm's price target on Encompass Health to $140 from $135 and keeps an Overweight rating on the shares. The firm recently spent time with Encompass Health's management team at the company's Birmingham headquarters and hosted a group call with investors. KeyBanc believes Encompass Health is well positioned to sustain attractive growth, given IRF supply-demand dynamics and visible market share opportunities. Upside drivers from the first half of the year seem sustainable to us, including the favorable mix of VA patients. Policy backdrop for IRFs remains benign. Leverage and free cash flow may support an accelerated pace of buybacks.

BofA

Buy

maintain

$145 -> $160

2025-09-10

Reason

BofA

Price Target

$145 -> $160

2025-09-10

maintain

Buy

Reason

BofA raised the firm's price target on Encompass Health to $160 from $145 and keeps a Buy rating on the shares. While hospital fundamentals should remain solid in the second half, the firm is concerned that the policy and reimbursement environment will be more negative compared to recent years, says the analyst, who prefers post-acute over hospitals as the least exposed to the upcoming cuts given this backdrop. The firm is updating estimates and price targets for several companies in its health care facilities coverage.

Truist

David MacDonald

Buy

maintain

$135 -> $140

2025-08-14

Reason

Truist

David MacDonald

Price Target

$135 -> $140

2025-08-14

maintain

Buy

Reason

Truist analyst David MacDonald raised the firm's price target on Encompass Health to $140 from $135 and keeps a Buy rating on the shares after meeting with management. The firm believes Encompass is seeing "robust" fundamentals due to strong demand trends and its scale. Ongoing labor improvement, increased artificial intelligence investment and the company's development activity further support a bullish stance on shares, the analyst tells investors in a research note.

UBS

Buy

upgrade

$130 -> $140

2025-08-06

Reason

UBS

Price Target

$130 -> $140

2025-08-06

upgrade

Buy

Reason

UBS raised the firm's price target on Encompass Health to $140 from $130 and keeps a Buy rating on the shares. Fundamentals remained strong in Q2, the analyst tells investors in a research note.

Mizuho

Outperform

maintain

2025-07-16

Reason

Mizuho

Price Target

2025-07-16

maintain

Outperform

Reason

Mizuho views the selloff yesterday in shares of Encompass Health following the New York Times report questioning the quality of the company's care as overdone. The article "presents a selective one-sided perspective," the analyst tells investors in a research note. Mizuho says the ten patients mentioned in the article represent less than 0.001% of all Encompass patients since 2021. The firm believes the company's earnings viability remains high and reiterates an Outperform rating on the name. It would buy the stock on the weakness.

Valuation Metrics

The current forward P/E ratio for Encompass Health Corp (EHC.N) is 18.83, compared to its 5-year average forward P/E of 19.40. For a more detailed relative valuation and DCF analysis to assess Encompass Health Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

19.40

Current PE

18.83

Overvalued PE

21.43

Undervalued PE

17.37

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

11.05

Current EV/EBITDA

10.69

Overvalued EV/EBITDA

11.87

Undervalued EV/EBITDA

10.22

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.49

Current PS

1.70

Overvalued PS

1.74

Undervalued PS

1.25

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

EHC News & Events

Events Timeline

No data

News

9.5

01-09Newsfilter

PinnedEncompass Health to Report Q4 2025 Results on February 5, 2026

9.5

01-09PRnewswire

Encompass Health to Report Q4 2025 Results on February 5, 2026

6.5

01-07Benzinga

BofA Cautious on Hospitals, Forecasts 2-4% EBITDA Headwind Over Next 5 Years

People Also Watch

Frequently Asked Questions

What is Encompass Health Corp (EHC) stock price today?

The current price of EHC is 102.93 USD — it has decreased -1.96 % in the last trading day.

What is Encompass Health Corp (EHC)'s business?

Encompass Health Corporation is an owner and operator of inpatient rehabilitation hospitals in the United States. The Company provides compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and treatments to maximize recovery. It operates hospitals in 38 states and Puerto Rico, with concentrations in Florida and Texas. It operates approximately 166 inpatient rehabilitation hospitals. Its inpatient rehabilitation hospitals offer specialized rehabilitative care across an array of diagnoses and deliver comprehensive patient care services. It provides care to patients who suffer from cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures and a variety of debilitating neurological conditions. Its hospitals have settings for treating the debilitating effects of the COVID-19 virus, such as significant muscle weakness, cognitive impairments, shortness of breath with activity and malnutrition.

What is the price predicton of EHC Stock?

What is Encompass Health Corp (EHC)'s revenue for the last quarter?

Encompass Health Corp revenue for the last quarter amounts to 1.48B USD, increased 9.36 % YoY.

What is Encompass Health Corp (EHC)'s earnings per share (EPS) for the last quarter?

Encompass Health Corp. EPS for the last quarter amounts to 1.23 USD, increased 17.14 % YoY.

What changes have occurred in the market's expectations for Encompass Health Corp (EHC)'s fundamentals?

How many employees does Encompass Health Corp (EHC). have?

Encompass Health Corp (EHC) has 23564 emplpoyees as of January 10 2026.

What is Encompass Health Corp (EHC) market cap?

Today EHC has the market capitalization of 10.36B USD.